Equity Overview
Price & Market Data
Price: $3.71
Daily Change: -$0.11 / 2.96%
Range: $3.70 - $4.00
Market Cap: $2,733,631
Volume: 6,355
Performance Metrics
1 Week: -1.01%
1 Month: -0.96%
3 Months: 21.31%
6 Months: -13.27%
1 Year: -63.31%
YTD: -11.83%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.